Merus N v (MRUS)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
Merus N.V.: Pioneering New Hope in EGFRm NSCLC Treatment while Achieving Impressive Revenue Growth
Loss larger than a year ago at the Merus N V in the April to June 30 2023 fiscal period
The Top-line took a nose-dive at the company amid the fiscal interval ending December 31 2022
Critical quarter for the company amid the fiscal span ending September 30 2022
The investors are dealing with 2.464%, elevation at MRUS in the April to June 30 2022 interval
Very impressive 63.143%, jump in revenue at Merus N V amid the fiscal period closing Dec 31 2021